Cargando…

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

INTRODUCTION: The treatment of diabetes has a significant impact on the pathogenesis of non-alcoholic fatty liver disease (NAFLD). We compared the effectiveness of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, and pioglitazone for the treatment of NAFLD patients with type 2 di...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoneda, Masato, Honda, Yasushi, Ogawa, Yuji, Kessoku, Takaomi, Kobayashi, Takashi, Imajo, Kento, Ozaki, Anna, Nogami, Asako, Taguri, Masataka, Yamanaka, Takeharu, Kirikoshi, Hiroyuki, Iwasaki, Tomoyuki, Kurihashi, Takeo, Saito, Satoru, Nakajima, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888333/
https://www.ncbi.nlm.nih.gov/pubmed/33593749
http://dx.doi.org/10.1136/bmjdrc-2020-001990
_version_ 1783652141225738240
author Yoneda, Masato
Honda, Yasushi
Ogawa, Yuji
Kessoku, Takaomi
Kobayashi, Takashi
Imajo, Kento
Ozaki, Anna
Nogami, Asako
Taguri, Masataka
Yamanaka, Takeharu
Kirikoshi, Hiroyuki
Iwasaki, Tomoyuki
Kurihashi, Takeo
Saito, Satoru
Nakajima, Atsushi
author_facet Yoneda, Masato
Honda, Yasushi
Ogawa, Yuji
Kessoku, Takaomi
Kobayashi, Takashi
Imajo, Kento
Ozaki, Anna
Nogami, Asako
Taguri, Masataka
Yamanaka, Takeharu
Kirikoshi, Hiroyuki
Iwasaki, Tomoyuki
Kurihashi, Takeo
Saito, Satoru
Nakajima, Atsushi
author_sort Yoneda, Masato
collection PubMed
description INTRODUCTION: The treatment of diabetes has a significant impact on the pathogenesis of non-alcoholic fatty liver disease (NAFLD). We compared the effectiveness of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, and pioglitazone for the treatment of NAFLD patients with type 2 diabetes mellitus. RESEARCH DESIGN AND METHODS: This open-label, prospective, single-center, randomized clinical trial recruited NAFLD patients with type 2 diabetes mellitus and a hepatic fat fraction of at least 10% as assessed based on the MRI-proton density fat fraction (MRI-PDFF). Eligible patients were stratified according to hemoglobin A1c (HbA1c), alanine transaminase, and MRI-PDFF levels and randomly assigned (1:1) to receive either 20 mg tofogliflozin or 15–30 mg pioglitazone, orally, once daily for 24 weeks. The primary endpoint was an absolute change in MRI-PDFF at 24 weeks. Efficacy and safety was assessed in all treated patients. This trial was registered in the Japan Registry of Clinical Trials. RESULTS: Overall, 40 eligible patients were randomly assigned to receive tofogliflozin (n=21) or pioglitazone (n=19). Changes in hepatic steatosis after 24 weeks of treatment were evaluated by MRI-PDFF, which showed a significant decrease in both groups (−7.54% (p<0.0001) and −4.12% (p=0.0042) in the pioglitazone and tofogliflozin groups, respectively). Compared with baseline, the body weight decreased by 2.83±2.86 kg (−3.6%, p=0.0443) in the tofogliflozin group and increased by 1.39±2.62 kg (1.7%, p=0.0002) in the pioglitazone group after 24 weeks. No life-threatening events or treatment-related deaths occurred. CONCLUSIONS: Tofogliflozin was well tolerated, and it reduced the MRI-PDFF levels in NAFLD patients with type 2 diabetes mellitus. TRIAL REGISTRATION NUMBER: jRCTs031180159.
format Online
Article
Text
id pubmed-7888333
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78883332021-03-03 Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial Yoneda, Masato Honda, Yasushi Ogawa, Yuji Kessoku, Takaomi Kobayashi, Takashi Imajo, Kento Ozaki, Anna Nogami, Asako Taguri, Masataka Yamanaka, Takeharu Kirikoshi, Hiroyuki Iwasaki, Tomoyuki Kurihashi, Takeo Saito, Satoru Nakajima, Atsushi BMJ Open Diabetes Res Care Metabolism INTRODUCTION: The treatment of diabetes has a significant impact on the pathogenesis of non-alcoholic fatty liver disease (NAFLD). We compared the effectiveness of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, and pioglitazone for the treatment of NAFLD patients with type 2 diabetes mellitus. RESEARCH DESIGN AND METHODS: This open-label, prospective, single-center, randomized clinical trial recruited NAFLD patients with type 2 diabetes mellitus and a hepatic fat fraction of at least 10% as assessed based on the MRI-proton density fat fraction (MRI-PDFF). Eligible patients were stratified according to hemoglobin A1c (HbA1c), alanine transaminase, and MRI-PDFF levels and randomly assigned (1:1) to receive either 20 mg tofogliflozin or 15–30 mg pioglitazone, orally, once daily for 24 weeks. The primary endpoint was an absolute change in MRI-PDFF at 24 weeks. Efficacy and safety was assessed in all treated patients. This trial was registered in the Japan Registry of Clinical Trials. RESULTS: Overall, 40 eligible patients were randomly assigned to receive tofogliflozin (n=21) or pioglitazone (n=19). Changes in hepatic steatosis after 24 weeks of treatment were evaluated by MRI-PDFF, which showed a significant decrease in both groups (−7.54% (p<0.0001) and −4.12% (p=0.0042) in the pioglitazone and tofogliflozin groups, respectively). Compared with baseline, the body weight decreased by 2.83±2.86 kg (−3.6%, p=0.0443) in the tofogliflozin group and increased by 1.39±2.62 kg (1.7%, p=0.0002) in the pioglitazone group after 24 weeks. No life-threatening events or treatment-related deaths occurred. CONCLUSIONS: Tofogliflozin was well tolerated, and it reduced the MRI-PDFF levels in NAFLD patients with type 2 diabetes mellitus. TRIAL REGISTRATION NUMBER: jRCTs031180159. BMJ Publishing Group 2021-02-16 /pmc/articles/PMC7888333/ /pubmed/33593749 http://dx.doi.org/10.1136/bmjdrc-2020-001990 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Metabolism
Yoneda, Masato
Honda, Yasushi
Ogawa, Yuji
Kessoku, Takaomi
Kobayashi, Takashi
Imajo, Kento
Ozaki, Anna
Nogami, Asako
Taguri, Masataka
Yamanaka, Takeharu
Kirikoshi, Hiroyuki
Iwasaki, Tomoyuki
Kurihashi, Takeo
Saito, Satoru
Nakajima, Atsushi
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
title Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
title_full Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
title_fullStr Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
title_full_unstemmed Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
title_short Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
title_sort comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (topind study): a randomized prospective open-label controlled trial
topic Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888333/
https://www.ncbi.nlm.nih.gov/pubmed/33593749
http://dx.doi.org/10.1136/bmjdrc-2020-001990
work_keys_str_mv AT yonedamasato comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT hondayasushi comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT ogawayuji comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT kessokutakaomi comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT kobayashitakashi comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT imajokento comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT ozakianna comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT nogamiasako comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT tagurimasataka comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT yamanakatakeharu comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT kirikoshihiroyuki comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT iwasakitomoyuki comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT kurihashitakeo comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT saitosatoru comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial
AT nakajimaatsushi comparingtheeffectsoftofogliflozinandpioglitazoneinnonalcoholicfattyliverdiseasepatientswithtype2diabetesmellitustopindstudyarandomizedprospectiveopenlabelcontrolledtrial